EUCTR2019-000951-14-GB进行中（未招募）1 期
A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer - BRaVac
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- RhoVac ApS
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Men aged 18 and above with an earlier histologic diagnosis of prostatic adenocarcinoma.
- •2. Able to understand the study procedures and willing to provide IC.
- •3. Able and willing to comply with study requirements and complete all visits.
- •4. Biochemical recurrence (BCR) in compliance with the following 3 conditions:
- •- after having finished last definitive treatment (including those who have received RP/RT
- •followed by any modality of salvage therapy),
- •- no distant metastasis by standard CT imaging with bone scintigraphy or a normal PETCT
- •- no locoregional recurrence (including lymph nodes). Locoregional recurrence will be assessed by multi-parametric magnetic resonance imaging (MRI) in all patients treated
- •with curative RT and should be confirmed with image guided prostatic gland biopsy in
- •case of suspicious lesions. Any prostatic biopsy performed should be negative.
- •5. Prior definitive treatment with RP or RT. In case the patient was subjected to a RP, all the
- •following will apply:
- •a. PSA =0.2 ng/mL,
- •b. PSA Doubling Time (PSADT)a >3 months and <12 months,
- •c. History of Gleason 7 (4 + 3) or higher.
- •Conversely, if the patient was treated with definitive RT and not prior RP, all the following
- •will apply:
- •a. PSA >nadira + 2 ng/mL,
- •b. PSADTa >3 months and <12 months,
- •c. History of Gleason score of 7 (4 + 3) or higher.
- •6. Eastern Cooperative Oncology Group (ECOG) performance status =2.
- •7. Laboratory values obtained =30 days prior to first vaccination
- •a. Hemoglobin =5.6 mmol/L (90 g/L)
- •b. Absolute granulocyte count =1.5 x 109 /L.
- •c. Platelets =100 x 109 /L.
- •d. Total bilirubin =1.5 x upper limit of normal (ULN).
- •e. Creatinine =1.5 x ULN.
- •f. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline
- •phosphatase (ALP) =2.5 x ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •1. Patients who are receiving androgen-deprivation therapy (ADT) or considered a candidate
- •for immediate ADT or are candidate to any local therapy according to applicable clinical
- •guidelines or judged by the investigator.
- •2. Patients who have received prior ADT are not eligible with the exception of those that
- •received ADT =36 months in duration and =9 months before randomization and
- •administered only in the neoadjuvant/adjuvant setting.
- •3. Patient is planned for salvage therapy.
- •4. Castrate level of serum testosterone <50 ng/dL at screening.
- •5. PSA >10 ng/mL.
- •6. Small-cell, signet cell and neuroendocrine variants of adenocarcinomas.
- •7. An active malignancy likely to interfere with protocol treatment or FU.
- •8. Patients who have undergone major surgery or have had major bleeding within the last
- •month prior to the first vaccination.
- •9. Prior treatment with any therapeutic cancer vaccine(s).
- •10. Participants with a condition requiring systemic treatment with either corticosteroids (>10
- •mg daily prednisone equivalent) or other immunosuppressive medications within 14 days
- •of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses >10
- •mg daily prednisone equivalent, are permitted in the absence of active autoimmune
- •11. History of alcohol or substance abuse within the last 5 years.
- •12. Patients receiving any investigational drug(s) or treatment within 30 days prior to
- •inclusion in this trial.
- •13. History of significant autoimmune disease such as Inflammatory Bowel Disease, Systemic
- •Lupus Erythematosus, Ankylosing Spondylitis, Scleroderma, Multiple Sclerosis.
- •14. Severe medical conditions, such as but not limited to severe asthma/chronic obstructive
- •pulmonary disease (COPD), New York Heart Association (NYHA) grading 3 or above, poorly
- •regulated insulin dependent diabetes, any significant organ damage as judged by the
- •Investigator.
- •15. Other medications, conditions or laboratory results that in the Investigator's opinion would
- •contraindicate study participation for safety reasons or interfere with the interpretation of
- •study results.
- •16. History of known allergy/hypersensitivity to any component of the study drug (such as
- •Montanide ISA 51), or intolerance to SC injection.
- •17. Patients with a prior solid organ / stem cell transplantation
- •18. Patients with known acquired immunodeficiency disorder (AIDS) or
- •any inherited immunodeficiency disorder
研究者
相似试验
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate CancerMedDRA version: 20.0Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 100000004864Prostate cancerEUCTR2019-000951-14-SERhoVac ApS180
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate CancerProstate cancerEUCTR2019-000951-14-FIRhoVac ApS180
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate CancerMedDRA version: 20.0Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 100000004864Prostate cancerEUCTR2019-000951-14-DERhoVac ApS180
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate CancerProstate cancerEUCTR2019-000951-14-DKRhoVac ApS180
进行中（未招募）
不适用
A study in patients with chondrosarcoma comparing IPI-926 to placeboEUCTR2010-024518-74-ESInfinity Pharmaceuticals, Inc169